

ORIGINAL RESEARCH

- 209279** The impact of co-occurring mental health problems on referral to and initiation of treatment among youth under probation supervision: Findings from a cluster randomized trial
Jennifer N. Stanley, Sarah C. DeLucca, Lauren Perron and Steven Belenko
- 209282** Latent class analysis of emergency department patients engaged in telehealth peer recovery support services and associations of identified classes with post-discharge outcomes
Dennis P. Watson, James A. Swartz, Lauren A. Magee, Bethany C. Bray, Peter Phalen, Spencer Medcalf and Alan B. McGuire
- 209237** Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective
Sun A. Choi, Connie H. Yan, Nicole M. Gastala, Daniel R. Touchette and Paul M. Stranges
- 209277** Prompt access to outpatient care post-incarceration among adults with a history of substance use: Predisposing, enabling, and need-based factors
Cici McNamara, Steven Cook, Lars M. Brown, Mari Palta, Kevin A. Look, Ryan P. Westergaard and Marguerite E. Burns
- 209298** Medications for opioid use disorder associated with reduced readmissions for patients with severe injection-related infections: A matched cohort study
Nicole M. Robertson, Anthony A. Mangino, Anna-Maria South and Laura C. Fanucchi
- 209296** Cognitive behavioral therapy for anxiety and opioid use disorder: Development and pilot testing
R. Kathryn McHugh, Garrett M. Fitzmaurice, Victoria R. Votaw, Rachel B. Geyer, Kael Ragnini, Shelly F. Greenfield and Roger D. Weiss
- 209286** Type-switching of short-acting nicotine replacement therapy products and its implications for treatment
Scott Veldhuizen, Laurie Zawertailo and Peter Selby
- 209295** Mental health treatment utilization among Gulf War era veterans with probable alcohol use disorder
Pallavi Aurora, Catherine E. Paquette, Jean C. Beckham, Mary Jo Pugh, Nathan A. Kimbrel and Patrick S. Calhoun
- 209291** Disclosing Recovery: A pilot randomized controlled trial of a patient decision aid to improve disclosure processes for people in treatment for opioid use disorder
Valerie A. Earnshaw, Karen R. Sepucha, Jean-Philippe Laurenceau, S.V. Subramanian, E. Carly Hill, James Wallace, Natalie M. Brousseau, Claire Henderson, Elaine Brohan, Lynn M. Morrison and John F. Kelly
- 209297** Age moderates the association of optimism on craving during substance use disorder treatment
Martin Hochheimer, Justin C. Strickland, Jennifer D. Ellis, Jill A. Rabinowitz, J. Gregory Hobelmann, Maggie Ford and Andrew S. Huhn
- 209293** Sexual orientation-based microaggressions and cannabis use outcomes among sexual minority individuals: The impact of negative affect and coping-motivated cannabis use
Evan M. Threeton, Paige E. Morris and Julia D. Buckner
- 209306** Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022
B.E. Meyerson, D. Treiber, B.R. Brady, K. Newgass, K. Bondurant, K.G. Bentele, S. Samorano, C. Arredondo and N. Stavros
- 209307** Buprenorphine induced opioid withdrawal syndrome relieved by adjunctive Magnesium: A clinical trial
Mohammad Moshiri, Bitia Chaeideh, Mohsen Ebrahimi, Bitia Dadpour, Alireza Ghodsi, Atoosa Haghighizadeh and Leila Etemad
- 209308** Prevalence and associated risk factors of hepatitis C antibody and RNA among people who inject drugs in Puerto Rico
Yesenia Aponte-Meléndez, Benjamin Eckhardt, Chunki Fong, Adriana Padilla, Wanda Trinidad-Martínez, Eric Maldonado-Rodríguez, Nancy Agront and Pedro Mateu-Gelabert

(Contents continued from previous page)

- 209310** Barriers to retention in medications for opioid use disorder treatment in real-world practice
Vanessa I. Villamil, Natasha Underwood, Laura J. Cremer, Cherie R. Rooks-Peck, Xinyi Jiang and Gery P. Guy
- 209311** Associations between smoking and pain in early recovery in residential substance use treatment-seekers
Shelby L. Blaes, Ben Lewis, Scott Teitelbaum, Gary Reisfield and Jeff Boissoneault
- 209309** Statewide efforts to address the opioid epidemic: Results from a national survey of single state agencies
Miguel Antonio G. Estrada, Amanda J. Abraham, Christina M. Andrews and Colleen M. Grogan
- 209312** The impact of the 2014 military conflict in the east of Ukraine and the Autonomous Republic of the Crimea among patients receiving opioid agonist therapies
Anna Meteliuk, Yana Sazonova, Emily Goldmann, Shu Xu, Vadym Liutyi, Tetiana Liakh, Tetiana Spirina, Maryna Lekholetova, Zahedul Islam and Danielle C. Ompad

HEALTH EQUITY IN SUD TREATMENT


- 209280** Rural-urban disparities in the availability of hospital-based screening, medications for opioid use disorder, and addiction consult services
Berkeley Franz, Cory E. Cronin, Zoe Lindenfeld, Jose A. Pagan, Alden Yuanhong Lai, Noa Krawczyk, Bianca D. Rivera and Ji E. Chang

CORRIGENDUM

- 209245** Corrigendum to “Helping families heal in substance use treatment: A qualitative study about the role of peer support specialists with client families” [J. Subst. Addict. Treat. Volume 148, May 2023]
Katie Heiden-Rootes, Dixie Meyer, Michael Mancini, Megan Ferber, Jacob Eikenberry, Wenjin Wang, Fred Rottnek, Emily Jung and Sania V. Karir

Instructions for submitting an article to *The Journal of Substance Use & Addiction Treatment* may be found online at: <http://www.journalofsubstanceabusetreatment.com/authorinfo>

Cited in (Printed/On-line): Bibliographie Internationale/PASCAL; Biological Abstracts/BIOSIS; Current Contents/Current Contents Search; Excerpta Medica/EMBASE; Index Medicus/MEDLINE; Psychological Abstracts/PsycINFO; Social Science Citation Index/Social SciSearch; Sociological Abstracts/Sociological Abstracts; /HealthSTAR; /IAC Business A.R.T.S.; /Periodical Abstracts PlusText; /Toxline



The impact of the 2014 military conflict in the east of Ukraine and the Autonomous Republic of the Crimea among patients receiving opioid agonist therapies[☆]

Anna Meteliuk^{a,b,*}, Yana Sazonova^c, Emily Goldmann^{d,e}, Shu Xu^f, Vadym Liutyi^b, Tetiana Liakh^b, Tetiana Spirina^b, Maryna Lekholetova^b, Zahedul Islam^a, Danielle C. Ompad^{d,e}

^a Alliance for Public Health, Kyiv, Ukraine

^b Department of Social Pedagogy and Social Work, Borys Grinchenko Kyiv University, Kyiv, Ukraine

^c Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine

^d Department of Epidemiology, NYU School of Global Public Health, New York, NY, USA

^e Center for Drug Use and HIV/HCV Research, NYU School of Global Public Health, New York, NY, USA

^f Department of Biostatistics, NYU School of Global Public Health, New York, NY, USA

ARTICLE INFO

Keywords:

Buprenorphine
Methadone
Military conflict
Opioid agonist therapies (OAT)
People with opioid use disorder (OUD)
War
Ukraine

ABSTRACT

Background: Opioid agonist therapies (OAT) for people with opioid use disorders (OUD) have been available in Ukraine since 2004. This study assessed the effect of 2014 Russian invasion of Ukraine on OAT re-enrollment and retention in conflict areas.

Methods: We analyzed the Ukraine national registry of OAT patients containing 1868 people with OUD receiving OAT as of January 2014 in conflict areas (Donetsk, Luhansk, and the Autonomous Republic [AR] of the Crimea). We developed logistic regression models to assess the correlates of re-enrollment of OAT patients in government-controlled areas (GCA) from conflict areas and retention on OAT at 12 months after re-enrollment.

Results: Overall, 377 (20.2 %) patients were re-enrolled at an OAT site in a GCA from conflict areas, of whom 182 (48.3 %) were retained on OAT through 2021. Correlates of re-enrollment were residing in Donetsk (adjusted odds ratios (aOR) = 7.06; 95 % CI: 4.97–10.20) or Luhansk (aOR = 6.20; 95 % CI: 4.38–8.93) vs. AR Crimea; age 18–34 (aOR = 2.03; 95 % CI: 1.07–3.96) or 35–44 (aOR = 2.09; 95 % CI: 1.24–3.71) vs. ≥55 years, and being on optimal (aOR = 1.78; 95 % CI: 1.33–2.39) or high OAT dosing (aOR = 2.76; 95 % CI: 1.93–3.96) vs. low dosing. Correlates of retention were drug use experience 15–19 years (aOR = 3.69; 95 % CI: 1.47–9.49) vs. <14 years of drug use; take-home (aOR = 3.42; 95 % CI: 1.99–5.96) vs. daily on-site dosing, and optimal (aOR = 2.19; 95 % CI: 1.05–4.72) vs. low OAT dosing.

Conclusion: Our study showed that one-fifth of patients were re-enrolled at sites in GCA areas, less than half of re-enrolled patients were retained. Disruption of OAT has implications for drug-, HIV-, and HCV-related morbidity and mortality.

Funding: AM was funded by NIH-funded grant D43TW010562; DCO was funded by the NIDA-funded Center for Drug Use and HIV/HCV Research (P30DA011041).

1. Background

Opioid agonist therapies (OAT) are an effective means of HIV prevention among people who inject opioids (Bruce, 2010). OAT have been available in Ukraine beginning in 2004 with buprenorphine and evolved

into a large-scale national program in 2008 when methadone became available. Providing OAT has been a critical harm reduction strategy for people with opioid use disorder (OUD) in Ukraine, and is considered one of the most cost-effective approaches to reducing HIV infection in this population (Fairley et al., 2021). Retention in OAT has also been

[☆] Disclaimer: The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention (CDC).

* Corresponding author at: 24 Bulvarno-Kudriavska Str., Kyiv 03150, Ukraine.

E-mail address: meteliuk@gmail.com (A. Meteliuk).

<https://doi.org/10.1016/j.josat.2024.209312>

Received 26 September 2023; Received in revised form 26 January 2024; Accepted 4 February 2024

Available online 7 February 2024

2949-8759/© 2024 Published by Elsevier Inc.